Liqun Zhou, male, graduated from Beijing Medical University (now the Peking University Health Science Center) in 1992 with a Doctor of Medicine degree. He is currently a Chief Physician and Second-Level Professor at the Department of Urology, Peking University First Hospital, and a doctoral and postdoctoral supervisor. He also serves as the Director of the Peking University Institute of Urology, the Chair of the Urology Department at Peking University Health Science Center, a Distinguished Professor of Henan University under the "Zhishan" Talent Program, and an expert consultant for central healthcare services. With over 30 years of clinical and research experience in urology, his specialties include urological and genital system tumors and endourology, particularly the application of laparoscopic and robotic techniques in urology and the treatment of complex urological and genital tumors.
Education:
- September 1981 - August 1987: Bachelor of Medicine, Bethune Medical University (now Jilin University School of Medicine), English Medical Program.
- September 1987 - August 1992: Doctor of Medicine, Beijing Medical University (Peking University Health Science Center).
Work Experience:
- September 1992 - August 1997: Attending Physician, Department of Urology, Peking University First Hospital.
- February 1996 - February 1997: Visiting Scholar, Department of Urology and Molecular Biology, Kitasato University Hospital, Japan.
- September 1997 - August 2002: Associate Chief Physician, Department of Urology, Peking University First Hospital.
- September 1998 - August 2003: Associate Professor, Department of Urology, Peking University First Hospital.
- September 2002 - Present: Chief Physician/Doctoral Supervisor, Department of Urology, Peking University First Hospital.
- September 2003 - Present: Professor, Department of Urology, Peking University First Hospital.
Academic Positions:
- Honorary President and Former President of the Chinese Urological Association of Physicians (CUDA).
- Standing Committee Member of the Chinese Urological Association (CUA).
- Deputy Director of the Beijing Medical Association's Urology Branch.
- Director of the Urology Medicine Committee of the Chinese Association of University, Industry, and Research Cooperation.
- Director of the Regular Assessment Committee for Urologists of the Chinese Medical Doctor Association.
- Executive Deputy Director of the Postgraduate Medical Education Committee in Surgery (Urology) of the Chinese Medical Doctor Association.
- Vice Director of the Urology Committee of the Chinese Research Hospital Association.
- Standing Committee Member of the Chinese Medical Doctor Association's Endoscopy Branch.
- Chairman of the Chinese Urology and Genital Industry Technology Innovation Strategic Alliance.
- Director of the CUDA Minimally Invasive and Robotic Group.
- Deputy Director of the CUA Minimally Invasive Group.
- Director of the Upper Urinary Tract Urothelial Carcinoma (UTUC) Collaboration Group of CUA and CUDA.
- Director of the UTUC Diagnosis and Treatment Guidelines Expert Group of CUA.
- Editor-in-Chief of the Chinese Edition of the _Journal of Clinical Oncology_ (Urology and Genital Tumor Section).
- Deputy Editor-in-Chief of the _Chinese Journal of Urology_.
- Deputy Editor-in-Chief of the _Chinese Journal of Endourology and Minimally Invasive Urology_ (Electronic Version).
- Deputy Editor-in-Chief of the _Modern Urology Journal_.
- International Editorial Board Member of _The Journal of Urology_.
- Editorial board member of several journals and reviewer for multiple international English-language journals.
Main Academic Achievements:
- Published over 610 articles, including more than 260 in English, with over 160 as first or corresponding author.
- Led multiple national and provincial-level funds, including "863" and major projects from the Ministry of Science and Technology, the National Health Commission's major projects, multiple National Natural Science Foundation projects, and key projects in the fields of innovation and special features.
- Edited 7 monographs, translated 2 books, and contributed to numerous other publications.
Teaching Experience:
- Engaged in undergraduate, graduate, and continuing medical education for over 30 years, mentoring nearly 100 master's, doctoral, and postdoctoral students. Many students have received honors for outstanding graduation.
- Awarded the Peking University Teaching Excellence Award in 2024.
Awards and Honors:
-First-Completed Achievements:
- 7 national and ministerial-level awards, including the Second Prize of the Ministry of Education's Science and Technology Progress Award and the Second Prize of the Huaxia Medical Award.
- A total of 15 national and ministerial-level awards.
- Detailed Awards:
- 2024: Third Prize of the Chinese Medical Science and Technology Award for the establishment and application promotion of an innovative diagnosis and treatment system for urothelial carcinoma.
- 2023: First Prize of the Beijing Medical Science and Technology Award for the establishment and clinical application of key technologies of the domestic Kangdor robot surgical system.
- 2023: Technical Progress Award of the Chinese Hospital Association Hospital Science and Technology Innovation Award for the establishment and clinical application of key technologies of the domestic Kangdor robot surgical system.
- 2022: Second Prize of the Beijing Science and Technology Award for the establishment of an innovative prevention, diagnosis, and treatment system for urothelial carcinoma.
- 2021: Second Prize of the Chinese Research Hospital Association Medical Science and Technology Award for Innovation in Medical Research.
- 2021: Second Prize of the Chinese Hospital Association China Science and Technology Innovation Award.
- 2018: Third Prize of the Chinese Medical Science and Technology Award for the improvement, innovation, and promotion of minimally invasive urological techniques.
- 2018: Third Prize of the Beijing Medical Science and Technology Award for a series of studies on the characteristics of upper urinary tract urothelial carcinoma in the Chinese population.
- 2018: Third Prize of the Beijing Science and Technology Award for the improvement, innovation, and application of upper urinary tract repair techniques.
- 2017: Second Prize of the Huaxia Medical Science and Technology Award for the improvement, innovation, and promotion of minimally invasive urological techniques.
- 2015: Third Prize of the Chinese Medical Science and Technology Award for basic research and clinical application of pathogenic genes in renal clear cell carcinoma.
- 2013: Third Prize of the Beijing Science and Technology Award for the mechanism of action of nucleosome-binding protein (NSBP1) in the development of urological tumors.
- 2013: Second Prize of the Science and Technology Progress Award for basic research and clinical application of VHL gene-related renal cell carcinoma.
- 2012: Second Prize of the Huaxia Medical Science and Technology Award for the application and promotion of laparoscopic techniques in urology.
-2005: Second Prize of the Beijing Science and Technology Progress Award for the application and promotion of endourological techniques.
Top 20 Published Articles by Impact Factor:
1. Chen K, Zhang J, Guo Z, Ma Q, Xu Z, Zhou Y, Xu Z, Li Z, Liu Y, Ye X, Li X, Yuan B, Ke Y, He C, Zhou L#, Liu J, Ci W. Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer [J]. _Cell Research_, 2016, 26(1): 103-118. (IF2022 = 44.1)
2. Zhan Y, Chen Z, He S, Gong Y, He A, Li Y, Zhang L, Zhang X, Fang D, Li X, Zhou L#. Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder cancer cells by modulating SOX2 [J]. _Molecular Cancer_, 2020, 19(1): 25. (IF2022 = 37.3)
3. Su B, Zhao W, Shi B, Zhang Z, Yu X, Xie F, Guo Z, Zhang X, Liu J, Shen Q, Wang J, Li X, Zhang Z, Zhou L#. Let-7d suppresses growth, metastasis, and tumor macrophage infiltration in renal cell carcinoma by targeting COL3A1 and CCL7 [J]. _Molecular Cancer_, 2014, 13: 206. (IF2022 = 37.3)
4. Yang K, Wang X, Xu C, Li Z, Han G, Fan S, Chen S, Li X, Zhu H, Zhou L#, Li X. Totally Intracorporeal Robot-assisted Unilateral or Bilateral Ileal Ureter Replacement for the Treatment of Ureteral Strictures: Technique and Outcomes from a Single Center [J]. _European Urology_, 2023, S0302-2838(23)02784-7. (IF2022 = 23.4)
5. Yang K, Fan S, Wang J, Yin L, Li Z, Xiong S, Han G, Meng C, Zhang P, Li X, Zhou L#. Robotic-assisted Lingual Mucosal Graft Ureteroplasty for the Repair of Complex Ureteral Strictures: Technique Description and the Medium-term Outcome [J]. _European Urology_, 2022, 81(5): 533-540. (IF2022 = 23.4)
6. Xu Z, Ge G, Guan B, Lei Z, Hao X, Zhou Y, Shi Y, Lu H, Wang J, Peng D, Wu X, He H, Zhang B, Li X, Zhou L#, Ci W. Noninvasive Detection and Localization of Genitourinary Cancers Using Urinary Sediment DNA Methylomes and Copy Number Profiles [J]. _European Urology_, 2020, 77(2): 288-290. (IF2022 = 23.4)
7. Zhong W, Xia K, Liu L, Cheng S, Peng H, He W, Dong W, Liu H, Lai Y, Han H, Liu C, Zhang H, Li X, Ding G, Li X, Ma L, Zhou L#, Lin T, Huang J. Long-term survival after female pelvic organ-sparing radical cystectomy versus standard radical cystectomy: a multi-institutional propensity score-matched analysis [J]. _International Journal of Surgery_, 2023, 10: 1097. (IF2022 = 15.3)
8. Li Z, Xu H, Gong Y, Chen W, Zhan Y, Yu L, Sun Y, Li A, He S, Guan B, Wu Y, Xiong G, Fang D, He Y, Tang Q, Yao L, Hu Z, Mei H, He Z, Cai Z, Guo Y, Li X, Zhou L#, Huang W. Patient-Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug Screening [J]. _Advanced Science_, 2022, 9(4): e2103999. (IF2022 = 15.1)
9. Ge G, Han Y, Zhang J, Li X, Liu X, Gong Y, Lei Z, Wang J, Zhu W, Xu Y, Peng Y, Deng J, Zhang B, Li X, Zhou L#, He H, Ci W. Single-Cell RNA-seq Reveals a Developmental Hierarchy Super-Imposed Over Subclonal Evolution in the Cellular Ecosystem of Prostate Cancer [J]. _Advanced Science_, 2022, 9(15): e2105530. (IF2022 = 15.1)
10. Liang Y, Tan Y, Guan B, Guo B, Xia M, Li J, Shi Y, Yu Z, Zhang Q, Liu D, Yang X, Hao J, Gong Y, Shakeel M, Zhou L#, Ci W, Li X. Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma [J]. _Theranostics_, 2022, 12(18): 7745-7759. (IF2022 = 12.4)
11. Lu H, Liang Y, Guan B, Shi Y, Gong Y, Li J, Kong W, Liu J, Fang D, Liu L, He Q, Shakeel M, Li X, Zhou L#, Ci W. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma [J]. _Theranostics_, 2020, 10(10): 4323-4333. (IF2022 = 12.4)
12. Zhan Y, Chen Z, Li Y, He A, He S, Gong Y, Li X, Zhou L#. Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA [J]. _Journal of Experimental & Clinical Cancer Research_, 2018, 37(1): 273. (IF2022 = 11.3)
13. Li Y, Gong Y, Ning X, Peng D, Liu L, He S, Gong K, Zhang C, Li X, Zhou L#. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis [J]. _Journal of Experimental & Clinical Cancer Research_, 2018, 37(1): 276. (IF2022 = 11.3)
14. Zhang L, Xiong G, Fang D, Li X, Liu J, Ci W, Zhao W, Singla N, He Z, Zhou L#. Contralateral upper tract urothelial carcinoma after nephroureterectomy: the predictive role of DNA methylation [J]. _Journal of Experimental & Clinical Cancer Research_, 2015, 34(1): 5. (IF2022 = 11.3)
15. Ji S Q, Yao L, Zhang X Y, Li X S, Zhou L Q#. Knockdown of the nucleosome binding protein 1 inhibits the growth and invasion of clear cell renal cell carcinoma cells in vitro and in vivo [J]. _Journal of Experimental & Clinical Cancer Research_, 2012, 31(1): 22. (IF2022 = 11.3)
16. Wang P, Shi Y, Zhang J, Shou J, Zhang M, Zou D, Liang Y, Li J, Tan Y, Zhang M, Bi X, Zhou L#, Ci W, Li X. UCseek: ultrasensitive early detection and recurrence monitoring of urothelial carcinoma by shallow-depth genome-wide bisulfite sequencing of urinary sediment DNA [J]. _EBioMedicine_, 2023, 89: 104437. (IF2022 = 11.1)
17. Li Y, Guan B, Liu J, Zhang Z, He S, Zhan Y, Su B, Han H, Zhang X, Wang B, Li X, Zhou L#, Zhao W. MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma [J]. _EBioMedicine_, 2019, 44: 439-51. (IF2022 = 11.1)
18. Chen Z, He S, Zhan Y, He A, Fang D, Gong Y, Li X, Zhou L#. TGF
